AMGN vs ESPR
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. ESPR: Esperion commercializes NEXLETOL and NEXLIZET, first-in-class non-statin ACLY inhibitors proven to reduce cardiovascular risk in statin-intolerant or statin-unwilling patients with elevated cholesterol.
Side-by-side fundamentals
| Metric | AMGN | ESPR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $366.05 | $3.18 | |
| Market cap as of 2026-07-23 | $197.7B | $819M | |
| P/E as of 2026-07-23 | 25.34 | n/a | |
| PEG as of 2026-07-23 | 4.93 | n/a | |
| Net margin as of 2026-07-23 | +21.0% | -1.8% | AMGN higher |
| Gross margin as of 2026-07-23 | +74.0% | +68.4% | AMGN higher |
| Operating margin as of 2026-07-23 | +28.8% | +18.1% | AMGN higher |
| ROE as of 2026-07-23 | +89.4% | -59.5% | AMGN higher |
| ROA as of 2026-07-23 | +8.6% | -1.8% | AMGN higher |
| Debt / equity as of 2026-07-23 | 6.24 | 0.00 | ESPR lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.1% | +61.1% | ESPR higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +74.8% | ESPR higher |
| Dividend yield as of 2026-07-23 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.43 | 1.15 | |
| 1-year return as of 2026-07-22 close | +19.7% | +156.5% | ESPR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.